Clinical Diagnostics Market Report 2024

This Clinical Diagnostics industry report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The clinical diagnostics market size has grown strongly in recent years. It will grow from $71.23 billion in 2023 to $76.27 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to several factors, such as an increase in chronic disease incidence, greater use of point-of-care diagnostic products, a continuous rise in the number of tests driven by expanding patient populations, government funding, growing demand for personalized medicine, and a larger geriatric population.

The clinical diagnostics market size is expected to see strong growth in the next few years. It will grow to $101.29 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The projected growth during the forecast period can be attributed to several factors, including rising demand for early disease detection, the expansion of healthcare infrastructure, increased investments in research and development, growing interest in molecular diagnostics, and the increasing prevalence of lifestyle-related diseases. Key trends likely to impact this growth include technological advancements, digital pathology, the integration of artificial intelligence, the use of wearable health devices, and the expansion of telemedicine.

The rising incidence of chronic diseases is expected to drive growth in the clinical diagnostics market. Chronic diseases, which require ongoing medical management and are often worsened by unhealthy lifestyles, socioeconomic disparities, and aging populations, include conditions such as heart disease, diabetes, and cancer. Accurate diagnosis, disease monitoring, treatment management, early detection of complications, personalized medicine, risk assessment, and patient education are becoming increasingly critical. For instance, the National Center for Biotechnology Information (NCBI) has projected that the number of individuals aged 50 and above with chronic illnesses will increase by 99.5% by 2050, growing from 71.52 million in 2020 to 142.66 million. This rising incidence is fueling the demand for clinical diagnostics.

Key players in the clinical diagnostics market are focusing on innovative products, such as advanced liquid biopsy assays, which facilitate comprehensive genomic profiling of solid tumors. Liquid biopsy assays are minimally invasive tests that analyze blood samples to identify cancer-related biomarkers, including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). These assays offer valuable insights for diagnosis, treatment monitoring, and personalized medicine. For example, in November 2023, Illumina Inc. introduced the TruSight™ Oncology 500 ctDNA v2, a liquid biopsy assay designed to provide detailed genomic profiling of solid tumors. This assay enables precise detection of genetic mutations and alterations, enhancing personalized treatment strategies by offering comprehensive molecular profiles and supporting timely clinical decisions.

In May 2022, BioMérieux acquired Specific Diagnostics to bolster its rapid antimicrobial susceptibility testing capabilities. This acquisition aims to strengthen BioMérieux's role in addressing antimicrobial resistance and improving patient outcomes in clinical microbiology. Specific Diagnostics, based in the US, is known for its innovations in clinical diagnostics, particularly in microbiology.

Major companies operating in the clinical diagnostics market are Siemens Healthineers, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, FUJIFILM Corporation, Becton, Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Grifols S.A., Sonic Healthcare Limited, Hologic Inc., Illumina Inc., PerkinElmer Inc., bioMérieux S.A., Sysmex Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Ortho Clinical Diagnostics, BioReference Laboratories Inc., NeoGenomics Laboratories Inc.

North America was the largest region in the clinical diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clinical diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the clinical diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Clinical diagnostics involves the identification, diagnosis, and monitoring of diseases or medical conditions through a variety of laboratory tests, imaging techniques, and other diagnostic tools. This process includes analyzing and interpreting patient samples, medical history, and clinical data to provide accurate and timely information essential for diagnosing, treating, and managing diseases.

The primary types of clinical diagnostic tests are lab tests, imaging tests, and other diagnostic procedures. Lab tests are performed on samples such as blood, urine, or tissue to detect diseases, monitor health conditions, or assess the effectiveness of treatments. The products used in clinical diagnostics consist of instruments, reagents, and other related items. These diagnostic tools are employed by various end users, including hospital laboratories, diagnostic laboratories, point-of-care testing facilities, and other healthcare settings.

The clinical diagnostics market research report is one of a series of new reports that provides clinical diagnostics market statistics, including clinical diagnostics industry global market size, regional shares, competitors with a clinical diagnostics market share, detailed clinical diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the clinical diagnostics industry. This clinical diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical diagnostics market includes revenues earned by entities by providing services such as genetic testing, molecular diagnostics, pathology services, microbiology testing, and immunology testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The clinical diagnostics market also includes sale of imaging devices, laboratory analyzers, point-of-care testing devices, endoscopy equipment, and respiratory diagnostic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.